Clover Health Investments Corp - Ordinary Shares - Class A Stock News

Dr. Duncan's appointment to this prestigious role recognizes his extraordinary contributions to the actuarial profession and healthcare innovation over three decades Dr. Duncan's appointment to this prestigious role recognizes his extraordinary contributions to the actuarial profession and healthcare innovation over three decades

Clover Health Continues to Invest in Streamlining Provider Workflows and Reducing Administrative Burden Through Technology and Operational Improvements Clover Health Continues to Invest in Streamlining Provider Workflows and Reducing Administrative Burden Through Technology and Operational Improvements

The latest AI-powered feature in Counterpart Assistant streamlines documentation, enhances physician workflows, and raises the bar for value-based care across practice settings at no additional cost to users The latest AI-powered feature in Counterpart Assistant streamlines documentation, enhances physician workflows, and raises the bar for value-based care across practice settings at no additi...

WASHINGTON, D.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) – Clover Health CEO Andrew Toy today had the honor to deliver testimony before the U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health, positioning Clover as a national leader in AI-enabled healthcare transformation.

While Clover Health's Q2 earnings showed continued member and revenue growth, it dropped 30% since then due to higher medical costs that impacted all MA plan providers. Clover Health still maintains industry-leading medical cost ratios despite the short-term cost headwinds, a testament to its tech-based business model. The implementation of negotiated drug prices in 2026, combined with the 5.06...

Clover Health (CLOV) Q2 Sales Up 34%

Clover Health Investments, Corp. (NASDAQ:CLOV ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Andrew Toy - Co-Founder, CEO & Director Peter J. Kuipers - Chief Financial Officer Ryan Schmidt - Corporate Participant Investor Relations Analyst - Corporate Participant Conference Call Participants John Granville Pinney - Canaccord Genuity Corp., Research Division Ma...

Second quarter 2025 Medicare Advantage membership of 106,323, up 32% year-over-year Second quarter 2025 Total revenues of $478 million, up 34% year-over-year Second quarter 2025 profitability metrics with GAAP Net loss of $11 million, Adjusted EBITDA of $17 million, and Adjusted Net income of $17 million Updates Full Year 2025 Guidance: Increases Average Medicare Advantage membership to 104,000...